巴瑞替尼或雷夫利珠单抗治疗成人重症COVID-19的疗效与安全性(TACTIC-R):一项随机、平行组、开放标签、4期试验
TACTIC-R是一项在英国22家医院开展的4期、随机、平行组、开放标签平台试验,纳入风险评分提示ICU入住或死亡风险40%的成人重症COVID-19患者,1:1:1随机分配至单独标准治疗、标准治疗联合巴瑞替尼或标准治疗联合雷夫利珠单抗。主要复合终点为随机化至第14天(含)首次发生死亡、有创机械通气、体外膜氧合、心血管器官支持或肾衰竭的时间。巴瑞替尼组主要终点HR 1.11(95%CI 0.62-1.99),雷夫利珠单抗组HR 1.53(95%CI 0.88-2.67),均未达统计学显著;试验因无效提前终止。作者认为巴瑞替尼给药时间短可能解释与其他试验的差异,靶向补体C5a而非C5裂解的潜在价值需进一步评估。
要点
- 重症COVID-19住院成人中,巴瑞替尼对比单独标准治疗主要复合终点HR 1.11(95%CI 0.62-1.99),未达统计学显著。
- 雷夫利珠单抗对比单独标准治疗主要复合终点HR 1.53(95%CI 0.88-2.67),未达统计学显著。
- 巴瑞替尼组仅54/137例(39%)完成最大14天疗程,雷夫利珠单抗组132/135例(98%)接受预定剂量。
- 严重不良事件:标准治疗组45例(21例死亡),巴瑞替尼组57例(24例死亡),雷夫利珠单抗组60例(18例死亡)。
- 试验在主要中期分析后因无效提前终止,作者认为巴瑞替尼给药时间短可能解释与其他试验的差异。
适用人群与场景
- 年龄≥18岁的成人COVID-19住院患者,风险评分提示ICU入住或死亡风险为40%。
- 来自英国22家医院,2020年5月8日至2021年5月7日入组。
诊断标准与关键阈值
- 采用风险评分筛选,评分提示ICU入住或死亡风险为40%者纳入。
处置流程与药物剂量
- 随机1:1:1分配至单独标准治疗、标准治疗联合巴瑞替尼或标准治疗联合雷夫利珠单抗。
- 巴瑞替尼组仅54/137例(39%)接受最大14天疗程;雷夫利珠单抗组132/135例(98%)接受预定剂量。
研究设计与关键结果
- 4期、随机、平行组、开放标签平台试验,在英国22家医院纳入417例患者,随机分为单独标准治疗组145例、巴瑞替尼组137例、雷夫利珠单抗组135例。
- 主要复合终点为随机化至第14天(含)首次发生死亡、有创机械通气、体外膜氧合、心血管器官支持或肾衰竭的时间。
- 巴瑞替尼组对比单独标准治疗组主要终点HR 1.11(95%CI 0.62-1.99),未达统计学显著。
- 雷夫利珠单抗组对比单独标准治疗组主要终点HR 1.53(95%CI 0.88-2.67),未达统计学显著。
- 严重不良事件:标准治疗组45例(21例死亡),巴瑞替尼组57例(24例死亡),雷夫利珠单抗组60例(18例死亡)。
- 试验在主要中期分析后因无效提前终止。
证据类型、等级与局限
- 证据类型:4期随机、平行组、开放标签平台试验。
- 试验因无效提前终止;巴瑞替尼组仅39%完成最大14天疗程。
- 作者指出巴瑞替尼给药时间短可能解释本研究与其他试验的差异。
- 作者认为靶向补体C5活化产物C5a而非C5裂解的治疗潜力需进一步评估。
对床旁实践的改变
- 作者认为,在本研究给药方案下,巴瑞替尼和雷夫利珠单抗均未能降低重症COVID-19患者疾病严重程度,安全性与标准治疗相似。
- 作者指出巴瑞替尼给药时间短可能解释本研究与其他试验的差异。
- 作者认为靶向补体C5a而非C5裂解的治疗潜力需进一步评估。
指南或共识出处
- TACTIC-R试验,注册号ClinicalTrials.gov NCT04390464,发表于Lancet Respir Med。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, and ravulizumab, a monoclonal inhibitor of complement C5 activation, as an adjunct to standard of care for the treatment of adult patients hospitalised with COVID-19.
METHODS: TACTIC-R was a phase 4, randomised, parallel-arm, open-label platform trial that was undertaken in the UK with urgent public health designation to assess the potential of repurposing immunosuppressants for the treatment of severe COVID-19, stratified by a risk score. Adult participants (aged ≥18 years) were enrolled from 22 hospitals across the UK. Patients with a risk score indicating a 40% risk of admission to an intensive care unit or death were randomly assigned 1:1:1 to standard of care alone, standard of care with baricitinib, or standard of care with ravulizumab. The composite primary outcome was the time from randomisation to incidence (up to and including day 14) of the first event of death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure. The primary interim analysis was triggered when 125 patient datasets were available up to day 14 in each study group and we included in the analysis all participants who were randomly assigned. The trial was registered on ClinicalTrials.gov (NCT04390464).
FINDINGS: Between May 8, 2020, and May 7, 2021, 417 participants were recruited and randomly assigned to standard of care alone (145 patients), baricitinib (137 patients), or ravulizumab (135 patients). Only 54 (39%) of 137 patients in the baricitinib group received the maximum 14-day course, whereas 132 (98%) of 135 patients in the ravulizumab group received the intended dose. The trial was stopped after the primary interim analysis on grounds of futility. The estimated hazard ratio (HR) for reaching the composite primary endpoint was 1·11 (95% CI 0·62-1·99) for patients on baricitinib compared with standard of care alone, and 1·53 (0·88-2·67) for ravulizumab compared with standard of care alone. 45 serious adverse events (21 deaths) were reported in the standard-of-care group, 57 (24 deaths) in the baricitinib group, and 60 (18 deaths) in the ravulizumab group.
INTERPRETATION: Neither baricitinib nor ravulizumab, as administered in this study, was effective in reducing disease severity in patients selected for severe COVID-19. Safety was similar between treatments and standard of care. The short period of dosing with baricitinib might explain the discrepancy between our findings and those of other trials. The therapeutic potential of targeting complement C5 activation product C5a, rather than the cleavage of C5, warrants further evaluation.
FUNDING: UK Medical Research Council, UK National Institute for Health Research Cambridge Biomedical Research Centre, Eli Lilly and Company, Alexion Pharmaceuticals, and Addenbrooke's Charitable Trust.
参考来源
- Hall FC, Cheriyan J, Cope AP, et al. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial. Lancet Respir Med. 2023. PMID: 37977159. doi:10.1016/S2213-2600(23)00376-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。